Oscar Health reaffirms FY2023 guidance and 2024 EBITDA target; no new figures

Oscar Health, Inc.

Reaffirms full year 2023 guidance as provided in Q3 2023 earnings release (Nov 7, 2023).
Reaffirms target for Total Company Adjusted EBITDA profitability in 2024.
To provide interim membership update from 2024 open enrollment at JPM conference.
No specific financial results or new numbers disclosed in this filing.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Oscar Health, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and fiscal year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

The Company will reaffirm the updated full year 2023 guidance that it provided in its financial results press release for the third quarter of 2023 dated November 7, 2023. The Company will also reaffirm its target of Total Company Adjusted EBITDA profitability in 2024

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Oscar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-005574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.